Načítá se...
Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients with Chronic HCV Infection
Hepatitis C virus (HCV) infection is a major cause of end-stage liver disease, including decompensated cirrhosis and hepatocellular carcinoma. Over 95% of patients with HCV infection have achieved sustained virologic response at 12 weeks under the treatment of several pan-genotypic regimens approved...
Uloženo v:
| Vydáno v: | J Clin Transl Hepatol |
|---|---|
| Hlavní autoři: | , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
XIA & HE Publishing Inc.
2021
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7868694/ https://ncbi.nlm.nih.gov/pubmed/33604263 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.14218/JCTH.2020.00078 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|